Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts

Transplant Immunology

Volumn 19, Issue 1, 2008, Pages 12-19

  Wang, Feng ^a   He, Wentao ^a   Yuan, Jin ^a   Wu, Ke ^a   Zhou, Hongmin ^a   Zhang, Weina ^a   Chen, Zhonghua Klaus ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Galectin 9; Graft rejection; Skin transplantation; Th1 cell

Indexed keywords

ECALECTIN; GAMMA INTERFERON; IMMUNOGLOBULIN; MUCIN; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS LINKING; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IN VITRO STUDY; INTERFERON PRODUCTION; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; T LYMPHOCYTE; TH1 CELL;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; GALECTINS; GRAFT REJECTION; GRAFT SURVIVAL; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, VIRUS; RECOMBINANT PROTEINS; SKIN TRANSPLANTATION; TH1 CELLS; TH2 CELLS;

EID: 40849083349     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.01.008     Document Type: Article

References (29)

1. Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 76 (1994) 597-598
2. Cooper D.N. Galectinomics: finding themes in complexity. Biochim Biophys Acta 1572 (2002) 209-231
3. Cooper D.N., and Barondes S.H. God must love galectins; he made so many of them. Glycobiology 9 (1999) 979-984
4. Hirabayashi J., Hashidate T., Arata Y., Nishi N., Nakamura T., H., et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 1572 (2002) 232-254
5. Tureci O., Schmitt H., Fadle N., Pfreundschuh M., and Sahin U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem 272 (1997) 6416-6422
6. Wada J., and Kanwar Y.S. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 272 (1997) 6078-6086
7. Matsumoto R., Matsumoto H., Seki M., Hata M., Asano Y., Kanegasaki S., et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 273 (1998) 16976-16984
8. Asakura H., Kashio Y., Nakamura K., Seki M., Dai S., Shirato Y., et al. Selective eosinophil adhesion to fibroblast via IFN-gammainduced galectin-9. J Immunol 169 (2002) 5912-5918
9. Perillo N.L., Marcus M.E., and Baum L.G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76 (1998) 402-412
10. Zick Y., Eisenstein M., Goren R.A., Hadari Y.R., Levy Y., and Ronen D. Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconjugate J 19 (2004) 517-526
11. Kashio Y., Nakamura K., Abedin M.J., Seki M., Nishi N., Yoshida N., et al. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 170 (2003) 3631-3636
12. Perillo N.L., Pace K.E., Seilhamer J.J., and Baum L.G. Apoptosis of T cells mediated by galectin-1. Nature 378 (1995) 736-739
13. Yang R.Y., Hsu D.K., Yu L., Ni J., and Liu F.T. Cell cycle regulation by galectin-12, a new member of the galectin superfamily. J Biol Chem 276 (2001) 20252-20260
14. Irie A., Yamauchi A., Kontani K., Kihara M., Liu D., Shirato Y., et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 11 (2005) 2962-2968
15. Kasamatsu A., Uzawa K., Nakashima D., Koike H., Shiiba M., Bukawa H., et al. Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med 16 (2005) 269-273
16. Dai S.Y., Nakagawa R., Itoh A., Murakami H., Kashio Y., Abe H., et al. Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 175 (2005) 2974-2981
17. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415 (2002) 536-541
18. Meyers J.H., Chakravarti S., Schlesinger D., Illes Z., Waldner H., Umetsu S.E., et al. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol 6 (2005) 455-464
19. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6 (2005) 1245-1252
20. Yamanokuchi S., Ikai I., Nishitai R., Matsushita T., Sugimoto S., Shiotani T., et al. Asialo GM1 positive CD8+ T cells induce skin allograft rejection in the absence of the secondary lymphoid organs. J Surg Res 129 (2005) 57-63
21. Illigens B.M., Yamada A., Fedoseyeva E.V., Anosova N., Boisgerault F., Valujskikh A., et al. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol 63 (2002) 912-925
22. Youssef A.-R., Otley C., Mathieson P.W., and Smith R.M. Role of CD4+ and CD8+ T cells in murine skin and heart allograft rejection across different antigenic disparities. Transpl Immunol 13 (2004) 297-304
23. Sabatos C.A., Chakravarti S., Cha E., Schubart A., Sanchez-Fueyo A., Zheng X.X., et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 4 (2003) 1102-1110
24. van de Weyer P.S., Muehlfeit M., Klose C., Bonventre J.V., Walz G., and Kuehn E.W. A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem Biophys Res Commun 351 (2006) 571-576
25. Anderson A.C., and Anderson D.E. TIM-3 in autoimmunity. Curr Opin Immunol 18 (2006) 665-669
26. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 (2005) 233-240
27. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116 (2006) 1317-1326
28. Mobley J.L., Rigby S.M., and Dailey M.O. Regulation of adhesion molecule expression by CD8 T cells in vivo. II. Expression of L-selectin (CD62L) by memory cytolytic T cells responding to minor histocompatibility antigens. J Immunol 153 (1994) 5443-5452
29. Liu Y., Ng Y., and Lillehei K.O. Cell mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10 (2003) 138-147